When caring for a patient who has been admitted for his heart failure, the nurse observes that the patient is experiencing bradycardia. Which drug should be administered to patients who develop bradycardia?
Atropine
Cholestyramine
Inamrinone
Milrinone
The Correct Answer is A
A. Atropine is an anticholinergic medication that increases heart rate by blocking vagal effects on the heart, making it the first-line treatment for symptomatic bradycardia.
B. Cholestyramine is a bile acid sequestrant used to lower cholesterol levels and does not have any effects on heart rate.
C. Inamrinone is a phosphodiesterase inhibitor used in heart failure for inotropic support but is not specifically indicated for bradycardia management.
D. Milrinone is also a phosphodiesterase inhibitor used for heart failure but does not address bradycardia directly.
Free Nursing Test Bank
- Free Pharmacology Quiz 1
- Free Medical-Surgical Quiz 2
- Free Fundamentals Quiz 3
- Free Maternal-Newborn Quiz 4
- Free Anatomy and Physiology Quiz 5
- Free Obstetrics and Pediatrics Quiz 6
- Free Fluid and Electrolytes Quiz 7
- Free Community Health Quiz 8
- Free Promoting Health across the Lifespan Quiz 9
- Free Multidimensional Care Quiz 10
View Related questions
Correct Answer is C
Explanation
A. This insulin does not peak like short-acting insulin; glargine provides a consistent release of insulin without a peak effect.
B. Long-acting insulin is not meant to be taken with meals, as it provides basal control and is typically taken once daily, not with each meal.
C. This statement is correct; glargine provides a steady level of insulin over 24 hours, helping to maintain consistent blood glucose levels throughout the day and night.
D. Long-acting insulin is usually administered once daily, so stating that it must be given three times a day is incorrect.
Correct Answer is D
Explanation
A. Giving the drug with food may delay absorption but does not affect the extent of the first-pass effect.
B. Administering the drug in small, frequent doses may help maintain therapeutic levels but will not significantly alter the first-pass effect.
C. Limiting protein intake could reduce drug binding to proteins, but this is not a standard approach for managing first-pass metabolism.
D. Administering the drug intravenously bypasses the gastrointestinal tract and liver, avoiding the first-pass effect, thereby increasing the amount of free drug available to body cells.